Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephenie Lerose

Physician Assistant Smyrna, GA Physician Assistant

NPI 1326358920 CMS profile 10522698

4441 Atlanta Rd Se Suite 212, Smyrna, GA 30080

Open in the dashboard

General payments

$5,727

370 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephenie Lerose of Smyrna, GA is reported in the CMS Open Payments database as having received $5,727 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87 4
2024 General $133 10
2023 General $145 9
2022 General $2,810 174
2021 General $2,552 173

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephenie Lerose
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stephenie Lerose were reported at $87. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stephenie Lerose Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,552 $132 $37–$438 $132
2022 $2,810 $155 $48–$522 $149
2023 $145 $167 $52–$557 $160
2024 $133 $178 $55–$600 $164
2025 $87 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $904 70 payments
  2. Lilly USA, LLC $611 43 payments
  3. Abbott Laboratories $389 27 payments
  4. Sanofi-Aventis U.S. LLC $358 20 payments
  5. IBSA Pharma Inc. $315 24 payments
  6. Xeris Pharmaceuticals, Inc. $308 18 payments
  7. Corcept Therapeutics $263 16 payments
  8. Amgen Inc. $239 14 payments
  9. AstraZeneca Pharmaceuticals LP $233 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $232 14 payments
  11. Other $1,876 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,727 370 payments
Products named General payments · program years 2021–2025
  1. Ozempic $536 37 payments
  2. RYBELSUS $517 36 payments
  3. Tirosint $315 24 payments
  4. GVOKE PFS $293 17 payments
  5. TRULICITY $272 18 payments
  6. FreeStyle Libre 3 $263 18 payments
  7. Korlym $263 16 payments
  8. SOLIQUA 100/33 $238 14 payments
  9. FARXIGA $233 13 payments
  10. JARDIANCE $232 14 payments
  11. Other $3,779 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record